Last reviewed · How we verify

Semaglutide Pen Injector

University of Pennsylvania · FDA-approved active Small molecule

Semaglutide Pen Injector is a GLP-1 receptor agonist Small molecule drug developed by University of Pennsylvania. It is currently FDA-approved for Type 2 diabetes mellitus, Chronic weight management in adults with obesity or overweight with weight-related comorbidities. Also known as: Ozempic, Wegovy®, Wegovy, Placebo Semaglutide 1mg.

Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight.

Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight. Used for Type 2 diabetes mellitus, Chronic weight management in adults with obesity or overweight with weight-related comorbidities.

At a glance

Generic nameSemaglutide Pen Injector
Also known asOzempic, Wegovy®, Wegovy, Placebo Semaglutide 1mg, Placebo Ozempic
SponsorUniversity of Pennsylvania
Drug classGLP-1 receptor agonist
TargetGLP-1R
ModalitySmall molecule
Therapeutic areaDiabetes, Obesity
PhaseFDA-approved

Mechanism of action

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural hormone GLP-1. It stimulates pancreatic beta cells to release insulin in response to elevated blood glucose, delays gastric emptying to slow nutrient absorption, and acts on the central nervous system to reduce hunger and food intake. These combined effects result in improved glycemic control and significant weight loss.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Semaglutide Pen Injector

What is Semaglutide Pen Injector?

Semaglutide Pen Injector is a GLP-1 receptor agonist drug developed by University of Pennsylvania, indicated for Type 2 diabetes mellitus, Chronic weight management in adults with obesity or overweight with weight-related comorbidities.

How does Semaglutide Pen Injector work?

Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight.

What is Semaglutide Pen Injector used for?

Semaglutide Pen Injector is indicated for Type 2 diabetes mellitus, Chronic weight management in adults with obesity or overweight with weight-related comorbidities.

Who makes Semaglutide Pen Injector?

Semaglutide Pen Injector is developed and marketed by University of Pennsylvania (see full University of Pennsylvania pipeline at /company/university-of-pennsylvania).

Is Semaglutide Pen Injector also known as anything else?

Semaglutide Pen Injector is also known as Ozempic, Wegovy®, Wegovy, Placebo Semaglutide 1mg, Placebo Ozempic.

What drug class is Semaglutide Pen Injector in?

Semaglutide Pen Injector belongs to the GLP-1 receptor agonist class. See all GLP-1 receptor agonist drugs at /class/glp-1-receptor-agonist.

What development phase is Semaglutide Pen Injector in?

Semaglutide Pen Injector is FDA-approved (marketed).

What are the side effects of Semaglutide Pen Injector?

Common side effects of Semaglutide Pen Injector include Nausea, Vomiting, Diarrhea, Constipation, Abdominal pain, Hypoglycemia.

What does Semaglutide Pen Injector target?

Semaglutide Pen Injector targets GLP-1R and is a GLP-1 receptor agonist.

Related